- Home
- RGC vs INBX Comparison
RGC vs INBX Comparison
Compare RGC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGC | INBX |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 430.2M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RGC | INBX |
|---|---|---|
| Price | $21.00 | $80.11 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 298.0K | 242.1K |
| Earning Date | 10-24-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,400,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.09 | $10.81 |
| 52 Week High | $83.60 | $94.57 |
Technical Indicators
Market Signals| Indicator | RGC | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 61.10 | 49.85 |
| Support Level | $16.30 | $76.22 |
| Resistance Level | $26.42 | $94.57 |
| Average True Range (ATR) | 2.04 | 7.21 |
| MACD | 0.75 | -1.31 |
| Stochastic Oscillator | 49.32 | 28.54 |
Price Performance
Historical ComparisonAbout RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.